14 patients with lepromatous leprosy received twice daily injections of 10 Wg recombinant interleukin 2 (rIL2), by the intradermal route, in the skin of the back for 8 d (total dose, 160 P,g). Lymphokine administration was accomplished without drug toxicity, or the development of acute nerve damage. The majority ofpatients developed nontender axillary lymphadenopathy during the course of treatment . Local injection sites showed progressively larger zones of induration, peaking at 24 h and persisting for many days. Early 12-h reactions were of a macular, erythematous nature and exhibited an increasingly striking diurnal variation . The morning injection sites were three-to fourfold larger in diameter than those placed in the evening (9 am to 9 pm) . Systemic manifestations of intradermal rIL 2 administration were noted. Peripheral blood T cells, including CD4+ and CD8+ phenotypes, increased 2-2 .5-fold and NK cells increased sixfold . Elevations in [3H]TdR incorporation into peripheral blood mononuclear cells occurred to a variety of mycobacterial antigens, but not to those ofMycobacterium leprae . Within 2 wk, biopsies at sites far removed from the back showed increased infiltration of mononuclear cells in 12 of 14 patients. Immunocytochemistry revealed the presence of newly emigrated CD4+ T cells, monocytes, and dermal CD1+ Langerhans cells. Endothelial cells of small dermal vessels expressed major histocompatibility complex class II determinants on their surface. Transmission electron microscopy of these specimens revealed markedly enlarged endothelial cells with many surface projections extending into the lumen as well as extravasating lymphoid cells. The numbers of acid-fast M. leprae in the peripheral sites were examined by slit smear and in biopsies of matched leprosy lesions taken before and after IL-2 administration . Within 2 mo, slit smears showed a 0.5 log or greater reduction in 12 of 14 patients, with a mean for all patients tested of 0.5 log units. Biopsy specimens showed a 1 log unit or greater reduction in the bacterial index (B.I.) in 6 of 14 patients. Historical controls in this Nepalese population showed a 0.5 log unit reduction after multidrug therapy over a period of 12 mo. Thus, after 8 d of IL2 injections, a fivefold reduction in B.I. was observed during the first 2 mo of the study. Antibody levels against M. leprae phenolic glycolipid 1 (PGL1) and lipoarabinomanan B were markedly elevated after IL-2 injections, while PGL1 antigen levels were reduced. We conclude that the administration of rIL2 has had a significant effect in decreasing the total body burden ofM. leprae. This is accomplished by the influx ofmononuclear leukocytes from the circulation, the enhancement ofcell-mediated immunity, and the degradation ofleprosy bacilli . This occurs much more rapidly compared with multidrug chemotherapy alone.
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atients with lepromatous leprosy lack detectable cellular anergy is specific, and a vigorous cell-mediated response may immunity directed against Mycobacterium leprae . This occur to other mycobacterial species, indicating they have all the components necessary to mount a typical delayed-type hypersensitivity (DTH)l reaction . During the course of studies designed to dissect the various aspects of cell-mediated immunity, we discovered that the intradermal administration of 10-25 jig of the lymphokine IL2 will stimulate a reaction indistinguishable from an antigeninitiated DTH response (1) (2) (3) (4) , having the hallmarks: (a) induration and erythema at the site ; (b) extensive and prolonged dermal infiltration by T cells, monocytes, and Langerhans cells; (c) high CD4+/CD8+ T cell ratios in the emigratory population ; (d) the absence of infiltration by granulocytic elements; (e) differentiation of mononuclear phagocytes to epithelioid and giant cells; (f) enhanced growth of overlying keratinocytes and the induction of their MHC class II antigens and IP-10 synthesis; (g) the generation of circulating antigen-specific and -nonspecific cytotoxic effector cells; (h) the destruction of parasitized macrophages; (i) the killing and clearance of M. leprae .
When administered to patients with lepromatous leprosy, a single intradermal injection of 10-25 hg rIL2 reconstitutes the local cell-mediated reaction leading to the destruction of M. leprae in the cutaneous site (5). IL-2 inoculation also enhanced the responsiveness of circulating lymphocytes to antigens to which the patient had previously been sensitized (6). In addition, the level of antigen-specific T cell as well as nonselective lymphokine activated killer (LAK) cell cytotoxicity against susceptible cell line targets and human monocytes was increased (7) .
These encouraging results, obtained with one to three injections in the local dermal milieu, prompted us to extend these studies to a multiple dose regimen. After a total dose of 160 hg of rIIT2, administered at 10 -lAg injections each 12 h for 8 d (16 injections), the systemic cell-mediated immune response of lepromatous.leprosy patients is enhanced resulting in the reduction of the total body burden of leprosy bacilli.
Materials and Methods
Patient Population. 14 patients, 12-56 yr old, 10 with a clinical diagnosis of polar lepromatous leprosy (LL), two with subpolar lepromatous leprosy (SLL), and two with borderline lepromatous leprosy (BL) (8) , were selected for intradermal administration of rIIL2 (Cetus Corp ., Emeryville, CA) (see Table 1 ) . Patients were included in the study if they were diagnosed as LL/BL, had a bacterial index (B.I.) (at diagnosis) by slit smear of 3+ or higher, and had received multidrug therapy (MDT) for no longer than 6 mo . Patients were hospitalized at The Anandaban Leprosy Mission Hospital, Kathmandu, Nepal. Leprosy patients in reaction or on steroid treatment were excluded from the study. Patients were informed of the nature of the study and written consent was obtained from all participants .
Patients had been treated from 1 to 6 mo, and had received MDT After patients were admitted, routine laboratory tests were performed on blood and urine. A general clinical and neurological exam was conducted. These were repeated during and at the end of the study. All chemotherapy was continued during the trial. Slit smears taken from the same six sites including a lesion in each patient were obtained for B.I . evaluation and performed at the time of diagnosis. Patients were retested a day or two before 11,2 injection and at intervals thereafter. 30 historical controls were selected and evaluated for their rate of reduction in B.I . during 24 mo of therapy. The controls were age and sex matched, clinically matched, and had a mean ± S.D . B.I . at diagnosis of 3.6 ± 1.2 (range, 3-5+). Since all patients in the study had been treated (MDT) for at least 1 mo (mean, 4 mo), the rate of reduction in B.I . for the historical controls was calculated from 1 to 24 mo of MDT Starting after the initial 1 or 3 mo of MDT (which includes intensive daily MDT for the first 2 wk) a mean B.I . reduction of 0.6 or 0.5, respectively, log reduction per 12 mo of therapy was observed (for linear regression analysis for the best fit for all points plotted, see Fig. 7 inset) .
11,2 Administration. Human rIIL2 (1 .8 x 107 IU/mg protein) was transported and stored at 4°C until used . The lyophilized IL-2 was reconstituted in pyrogen-free sterile water and diluted in 5% dextrose to a concentration of 100 Fag/ml, and used within 2 h of reconstitution . Patients received a dose of 10 gg r1L2 at 12-h intervals into apparently normal skin of the back on alternate sides. Local erythema and induration of the injected site were evaluated twice daily.
Histopathology and Enumeration ofBacilli. Biopsies (wedge shaped, 1 cm in length) of matched, distal lepromatous lesions not injected with IL-2 and not in areas within the lymphatic drainage of injected sites were taken before, 5-13 d after the first IL2 injection, and 6 mo later. The biopsies taken before and 6 mo after 11,2 . injection were removed from the same lesion, and the 5-13-day biopsy was taken from another clinically matched lesion . In addition, a biopsy was taken from an area of the back not injected with IL-2 but within the lymphatic drainage of injected sites. Biopsies were cut into three parts and processed for evaluation . A part of each biopsy was fixed in 10% neutral buffered formalin overnight, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for histological diagnosis and with acid-fast staining for enumeration of M. leprae . A logarithmic index of bacilli in the biopsies (9, 10) was used to express bacterial numbers in sites obtained before, during, and after IL-2 injection.
Immunohistology. Biopsy specimens were fixed in paraformaldehyde (3%), lysine (0 .075 M), and sodium-m-peroxdate (0 .01 M) in PBS (PLP) for 3 h at 4°C as described (11) . This fixative preserves structural details without destroying the serological reactivity of the cell surface. The biopsies were washed in PBS containing sucrose (10%) and digitonin (5 x 10 -5 M) and then serially suspended in graded solutions of sucrose (15-25%) . The tissue was stored in PBS with sucrose/glycerol (25% and 5%, respectively) for transport back to the U.S. until frozen .
Biopsies were embedded in OCT compound and frozen at -20°C; 6-8-ttm sections were cut on a cryostat and applied to gelatin-coated multi-well slides (Carlson Scientific Inc., Peotone, IL). The sections were dried overnight at 37°C, rehydrated in PBS, and incubated with mouse mAbs followed by biotinylated horse anti-mouse Ig and then avidin-biotin peroxidase complexes (Vector Laboratories, Inc., Burlingame, CA) . The reaction product was de- Cell were also analyzed by flow cytometry. The buffer used throughout consisted of PBS containing 2% FCS, 0.1% NaN3, and normal human IgG (1 /AM) to block Fc receptor binding. PEconjugated mAbs reactive with CD3, CD4, CD8, and CD56 (NKH1) were obtained from Coulter Clone (Hialeah, FL). FITCconjugated mAbs reactive with the IL-2R p55 chain were from Coulter Clone and for the II.2R p75 chain (18) (TU27) were from Dr. Kazuo Sugamura (Tohoku University, Sendai, Japan) . The PE-conjugated and I1r2R p55 mAbs were used at a final dilution of 1:20, and the anti-111,2R. p75 was diluted 1:100. Cells were stained at 4°C for 1 h with two sets of mAbs to reveal nonspecific binding. One set of cells were stained in the presence of a 100-fold excess of unconjugated mAbs, and one set without unconjugated mAbs . After incubation, the cells were centrifuged, the supernatant removed, and 1 ml of PBS + 0.4% paraformaldehyde was added. The cells were stored at 4°C until analyzed by flow cytometry using a cytometer (Ortho Diagnostic Systems, Inc., Westwood, MA). At least 2,000 cells were analyzed in each preparation, and the percentage of positively stained cells was calculated .
Lymphoproliferative Assays. PBMC were prepared by Ficoll-Paque density separation and used to determine responses to the following stimuli: M. leprae (106 to 108 particles/ml) (batch CD-94, obtained from Dr. R. J. W Rees, Mill Hill, UK, through the WHO Immunology of Leprosy Programme) ; M. bovis Bacillus Calmette- IgG antilipoarabinomannan B (LAM-B) antibodies were measured by ELISA using M. tuberculosis LAM-B as antigen (provided by Dr. P. J. Brennan, Colorado State University, Fort Collins, CO) using the conditions described previously (24) .
Results

Experimental Design
There were two major considerations in the design of this experiment . The first was to use low, nontoxic doses of rIL2 and to study the local and systemic influences of the lym- The lymphokine was administered in a set pattern on the back starting in the paravertebral area at the level of T2 and placed -4 cm on either side of the spinous processes. The 9 am injection was given on the left side and the 9 pm on the right . Injections were then given in a descending fashion ending at a site in line with the upper pelvis . The local reactions were never overlapping.
The 12-h Site The initial injection of 10 jig 11,2 gave an area of induration of ti 14 mm in diameter and resembled in every way results obtained in a prior study (5) . With repeated injections interesting effects were observed in both 99 7 Kaplan et al .
the intensity and temporal nature of the local reaction . One of the first to be noted was the striking enhancement in the extent of the response at the 12-h time period (Fig. 1 A) . This reaction was characterized by the presence of an erythematous, raised, macular lesion with irregular margins and appeared to have a vascular component. At the time of the first evaluation (12 h), it covered an area of about twice the firm zone ofinduration found at the 24-h reading (Fig. 1 B) . With repeated injections, these sites were very much larger with long finger-like extensions extending much beyond the central zone. It became apparent by the end of the series that these larger responses were always the result of the 9 am injection and were enhanced after the fifth injection . This striking diurnal variation in the 12-h response is seen in Fig . 1 A . Indurated Sites. At 24 h and for several days later, the injected sites were firmly indurated . The largest area ofinduration occurred at 24 h, in keeping with our earlier results. Fig . 1 , B-D illustrates the sites read at 24, 36, and 48 h. It is clear that with repeated IL-2 injections the maximum zone of induration at 24 h increased by twofold. With the passage of time, both the diurnal variation and local enhancement of induration were less evident. This was the result of the temporal response seen in Fig. 2 . Although the maximum zone of induration was markedly affected by increasing the dose of 11,2, the subsequent decrudescence of the reaction occurred with similar kinetics so that by 72 h little difference was noted in the areas of induration.
From our previous studies we know that the 24-h site is already heavily infiltrated with newly emigrated T cells largely of the CD4+ phenotype (5) .
Local Skin Lesions. By the end ofthe course of 11,2 injection, two patients with extensive skin lesions over the entire back showed flattening of the lesions in the central region ofthe back, whereas more peripheral lesions were unaffected .
The Systemic Effects of rIL2
Clinical Course. Daily evaluations of the clinical state of patients during and after the 8-d course of 11,2 were performed. Other than mild pruritus, the indurated sites on the back gave no discomfort . A few patients developed a low grade fever (0.6-1.0°C) during the course of the injections, lasting a day or so without malaise. At times after the third day of treatment, nontender axillary lymphodenopathy was present in the majority of patients . Detailed examination of nerve conduction was performed each day by a trained observer. There was no evidence of any additional neural in- volvement either during or after the study. Neither weight gain nor edema were noted . One patient developed significant fever with swelling and erythema of skin lesions after 13 injections . There was no neural involvement . An acute infection, pharyngitis, had also developed at this time. The rIIr2 was stopped and the cutaneous reversal reaction resolved with corticosteroids.
Peripheral Blood Cells and their Phenotypes. The total and differential cell counts of peripheral blood obtained at times up to 13 d after the initiation of 11,2 injections are shown in Table 2 . A small enhancement in total white cells was noted, the majority of which was contributed by a 1.5-fold increase in mononuclear cells and a twofold increase in eosinophils. Neutrophil levels remained unchanged.
The phenotype of PBMC during this same period is shown in Table 3 . The number of B lymphocytes and monocytes remained essentially unchanged . T cell numbers increased by about two-fold, with the largest increment being evident in the CD4+ series. It was noteworthy that the number of NK cells increased sixfold starting from subnormal, initial levels . The low numbers of IL2R bearing cells (the p55 and p75 chains) did not increase.
In Vitro Lymphocyte Function . The responses ofPBMC to a variety of antigens expressed on whole M. leprae and BCG as well as proteins separated from these organisms is seen in Table 4 . Before IL2 injections, all but one patient failed to respond to M. leprae and its 18-kD protein. This nonreactivity persisted in samples collected during and immediately after the entire course of IL2. One patient demonstrated a positive proliferative response to whole M. leprae immediately after the course of rIL2 injections, but this reverted to negative in the assays at 2 and 6 mo. By comparison, most patients initially responded to whole BCG, PPD, and the 65-and 70-kD proteins of BCG. After IL2 injections, the cells from most patients showed an enhanced response to these antigens by factors oftwo-to fourfold . Therefore, it appeared that 11,2 enhanced lymphocyte reactivity to antigens that the patients had been previously sensitized to, but did not modify the selective anergy to M. leprae.
The cytotoxic activities ofNK and LAK cells before, during, and after IL2 injections were not appreciably altered. 13H]TdR incorporation was considered + when the stimulation index was >10, ± when the stimulation index was 6-10, and -when <5 .
t Activity was calculated as percent of [3H]TdR incorporation 5-13 d after initiation of IL-2 injection (see Table 1 ) evaluated as stimulation index relative to the pre-IL-2 response . -+  +  +  +  --317  270  152  155  3  --+  +  +  +  2995  -NT  144  377  NT  6  --+  +  +  +  -400  381  514  314  211  8  --+  +  +  +  --383  374  253  234  9  --+  +  +  +  --242  219  34  204  10  --±  ±  -_  --155  189  --11  --+  +  +  +  --163  731  280  186  13  --+  +  +  +  --155  413  235 T cell numbers were evaluated by direct microscopic counting of H + E-stained and immunohistological stained sections . (+). The relative numbers of T cells were at least doubled by both methods of evaluation ; (±) slight enhancement in T cell numbers was observed; (-) no change in T cell numbers was observed . t 6-mo post-IL-2 injection biopsy taken from a site on the back distal to the IL-2 injection area . S Biopsies that showed upgrading and the presence of epithelioid and multinucleated giant cells .
11 T cell numbers enhanced by H + E staining but not by immunohistological evaluation .
Immunocytochemistry and Histopathology of Peripheral Sites.
We have previously described the local response to IL2 inoculation, including the numbers and phenotypes ofemigratory cell populations (5) . In this study, we focused on changes at matching skin sites distal from the foci of IL-2 injections (sites not injected with nor in the area of drainage of IL2) . Within 13 d after the administration of rIL2, skin biopsies of 12 of 14 patients demonstrated an increase in lymphoid cells at peripheral sites (Table 5 and Fig. 3, A and B) .
By mAb analysis, the emigratory cells consisted largely of T lymphocytes, and CD4+ T cells were present in large numbers (Fig. 3, C and D) . This body-wide infiltrate also Transmission Electron Microscopy of Peripheral Sites. Glutaraldehyde-fixed specimens of skin biopsies of distal lesions were taken before and after IL2 administration . It is clear from Fig. 4 that the cellularity of the post-IL2 sites was considerably increased with a preponderance of lymphoid cells. This is in keeping with the H+E-stained sections illustrated in Fig. 3 . Parasitized macrophages and foam cells were clearly damaged and fragmented .
An unusual finding was made upon closer examination of the endothelial cells of small dermal vessels. These are seen in more detail in Fig. 5 . The endothelium of pre-IL2 sites is rather flat and contains numerous small endocytic vessels in keeping with the usual structure of capillaries (Fig. 5, A-C) . After IL2 injection, the endothelium became thickened with many long projections extending into the lumen, and larger cytoplasmic vacuoles were evident (Fig. 5, D-F) . Emigratory cells were observed between endothelial cells, and the lumen contained larger numbers ofmononuclear leukocytes. The basement membrane of the vessels was thickened and had an edematous appearance. Extravascular sites were essentially normal other than their increased cellularity, and a striking selective destruction of foam cells and other mononuclear phagocytes. The Fate ofM. Leprae. For slit smear analysis, the same, six sites were tested at various time points before and after 1162 injection, and theB.I. of the sites were reviewed by trained technical staff. The composite data on 14 patients is given in Table 5 . Upon slit smear analysis, 7 of 12 patients evaluated demonstrated 0.5 log or greater reduction in B.I. at 2 mo. A mean reduction of 0.5 log units for all patients tested at Figure 5 . Transmission electron micrograph demonstrating the effect of rII.2 administration on the small blood vessels of lepromatous lesions (see Fig. 4 ) . The endothelial surface forming the lumen (Lu) of the pre-IL2 sites (A-C) is relatively flat and regular (arrows in A and C) and contains many small, regular endocytic vesicles. The underlying collagen (coil) is normal . In the post-11,2 lesions (D-F), the endothelium is swollen with long projections into thevessel lumen (arrows) and largeirregular vacuoles . The underlying basement membrane is thickened andedematous (colt) E-erythrocytes . Thejunctions of the vasculature appear intact both before (B and C) and after (E) IL2 injection (curved arrow in B, C, and E) . A, D, and F, patient no. 11; B, C, and E, patient no. 14 . A, x4,600; B, x9,000; C, x 20,000; D, x 6,600; E, x 3,700; F, x11,000 .
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2 mo was observed (Table 5 and Fig. 6 ). An additional 0.1 log units reduction in B.I. was noted from 2 to 6 mo, suggesting that the effect of IIr2 injection on bacterial clearance was almost immediate and required the continuous presence of the lymphokine. Matched historical control BULL leprosy patients, not injected with IL2, were evaluated for B.I. reduction during 24 mo of MITT These controls demonstrated a 0.5-0.6 log unit reduction in B.I. during 12 mo of MDT or 0.08-0 .1 log units per 2 mo of therapy (Fig. 6) . Thus, consistent with these results from matched historical controls, a five-to sixfold increase ofclearance was observed during the 2 mo after only 8 d of IL2 injection . For biopsy analysis, examination of peripheral skin biopsies was performed before IL2 injections, 5-13 d after the initiation of IL2, and at 2 and 6 mo thereafter. These were obtained from leprosy lesions not injected with IL2 and not within the lymphatic drainage of the injected sites (primarily the arms and legs). Coded slides were examined for histological diagnosis, lymphocytic infiltrate, and bacillary indices by two independent investigators.
Bacterial indices evaluated from biopsy sections showed a 1 log or greater reduction in 6 of 14 patients already at the 5-13-d time point (Table 5 and Fig. 7 ). 6 mo after the course of IL2 injection, 7 of 12 patients showed B.I. reductions, at peripheral sites not exposed directly to IL2 (Table 5 , Fig.  8 ). Biopsy sites on the back showed a more striking decrease in bacillary load than elsewhere on the body. This zonal effect may be related to the lymphatic drainage of the area and the passage of a greater number of inflammatory cells from the centrally located IL2 sites .
Antibody Titers against M. leprae Components. Serum levels of PGIA were measured before and at various times after 11,2 injection . Antigen levels were high in the tested patients at the start of the study. However, after the initiation of IL2 injection, a sharp reduction in the levels of antigen in the serum was observed even within 2 wk of treatment. (Fig. 9 A) .
Antibody titers against M. leprae PGL1 and the polysaccharide antigen LAM-B were measured before and at various times after IL2 injections. All but one of our Nepalese patients had been treated with a multidrug regimen for 1-6 mo, and the IgM PGLl levels had fallen from pretreatment levels in some cases. 2 mo after IL2 injections, there was a rise in the IgM anti-PGLl levels, and by 6 mo, the levels were falling (Fig. 9 B) . The IgG anti-LAM-B levels increased about twofold only (data not shown) .
We suggest that the lymphokine-enhanced degradation and clearance of bacilli reduces the amount ofM. leprae antigens in the circulation. It also stimulates the synthesis ofantibodies directed at mycobacterial cell wall carbohydrates and lipids. This limited trial of rIIr2 administered intradermally has successfully modified the natural history of leprosy in the majority of patients. Low doses of the lymphokine have had clear systemic effects, including an elevation of the number of circulating mononuclear cells, a generalized infiltration of lymphocytes into the skin, and the subsequent rapid clearance of M. leprae (fivefold increase in the rate of clearance) as compared with the influence ofMDT alone. This occurred in the absence of significant IL-2 toxicity, and without precipitating an uncontrolled reactive state or additional peripheral neuropathy. Moreover, it has been achieved in an accelerated time frame measured in weeks rather than in years.
Our findings indicate that rIL2 has enhanced the generation of a more vigorous cell-mediated immune response in patients with lepromatous leprosy. This response has occurred without indication that we have stimulated specific anti-M. leprae cellular immunity, in that neither M. leprae-specific T cell mitogenesis nor the generation of cytotoxic effector cells to M. leprae antigen occurred. Even so, enhanced cellular reactivity was characterized by the: progressively increased zones of induration at the injection sites ; generalized cutaneous infiltration with T cells, monocytes, and Langerhans cells; a reduction in the bacillary index as determined by slit smears and biopsies; and a reduction in the size of skin lesions. The elevation in antibodies against M. leprae products is consistent with this interpretation and suggests a humoral immune response to a new antigenic load released from the tissues. In addition, the reduction in M. leprae PGL1 antigen levels is consistent either with a systemic reduction in bacillary load and/or the clearance of immune complexes.
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place during the course of 11,2 injections is the result of an increased number of emigratory cells entering the sites. This is in keeping with previous information on the relationship between induration, the percentage ofthe dermis infiltrated, and the percentage ofT cells in IIr2 and antigen-driven reactions (2, 5) . In a manner yet to be determined, prior IL2 injections influence the intensity of the local emigratory response. This may occur by sensitizing circulatory cells for the recognition of the local site and/or by modifying the endothelium of the local vasculature . As we observed, the endothelium of small, dermal vessels is structurally altered and expresses MHC determinants . This may promote the binding and transmigration of intraluminal mononuclear cells and may help explain the widespread influx of T cells into peripheral sites. One must also consider roles for other IIr2-induced lymphokines and cytokines (e.g., IFN -'y) in generating , local chemoattractants. We suspect that the efficacy of the emigratory response is in part the result of the pre-existing infiltrates that occur in the skin of lepromatous leprosy patients . Preliminary observations in patients with a normal dermal milieu, but receiving long-term IL2 therapy, show smaller numbers of infiltrating cells (G. Ritz, personal communication) . Finally, the 12-h responses are indicative of enhanced vascular permeability and functional alterations in the endothelium . The reduction in the number ofleprosy bacilli that occurs in both local and peripheral sites requires the destruction of aged, parasitized macrophages (3, 5) . This process is associated with the generation of effector cells that selectively recognize infected mononuclear phagocytes and spare other elements of the cutaneous site. Since we cannot document the enhancement ofM. leprae-specific cytotoxic T cells, it is likely that cells with less selective recognition mechanisms may be involved. These would include NK, LAK, and perhaps y/S+ T cells as likely candidates for this mechanism (7, 25) . These findings are consistent with prior results from the analysis of the cellular composition of antigen-initiated DTH responses : by far, the vast majority of cells emigrating to the site of antigen inoculation are not antigen-specific reactive T cells . From the results of this study, it appears that IL2 or an 11r2-induced product can act as a chemotactic signal for extravasation ofmononuclear leukocytes into the dermis, where these probably mediate the antimicrobial response we have observed.
These results support the conclusion that IL2 can reduce the total body burden ofM. leprae when combined with multiple drug chemotherapy in patients with leprosy. This effect appears to result from a controlled enhanced cell-mediated response and may be applicable to a number of other chronic infectious processes, including the opportunistic pathogens of AIDS. The partial responses obtained after only 8 d suggest that more prolonged administration of the lymphokine would be beneficial and might even be curative. Whether or not this form of immunotherapy will be applicable to a larger segment of leprosy patients is unclear. However, it is evident that a detailed analysis oflymphokine biology in man is central to our ability to manipulate the immune response in the future.
